Information Provided By:
Fly News Breaks for November 5, 2018
MNTA
Nov 5, 2018 | 04:59 EDT
Piper Jaffray analyst Danielle Brill started Momenta Pharmaceuticals with an Overweight rating and $35 price target. The company offers a "rare" biotech investment opportunity as its stock is "super cheap" and its anti-FcRn therapies could be game changing for treating auto-immune diseases, Brill tells investors in a research note. Momenta's proprietary pipeline has "major blockbuster potential and is underappreciated by investors," says the analyst.
News For MNTA From the Last 2 Days
There are no results for your query MNTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.